tion Service to appoint an arbitrator from the 
roster of arbitrators maintained by such Service 
or a hearing with a regional office of the Amer-
ican Arbitration Association. A copy of the re-
quest shall be sent to each person from whom 
the requesting party seeks compensation or who 
seeks compensation from that party. 
‘‘(B) NO REVIEW OF FINDINGS AND DE-
TERMINATION.—The findings and determina-
tion of the arbitrator in a dispute initiated pur-
suant to subparagraph (A) shall be final and 
conclusive, and no official or court of the 
United States shall have power or jurisdiction 
to review any such findings and determination, 
except in the case of fraud, misrepresentation, 
or other misconduct by one of the parties to the 
arbitration or by the arbitrator. 
‘‘(C) PAYMENT OF FEE AND EXPENSES.— 
The parties to arbitration initiated pursuant to 
subparagraph (A) shall share equally in the 
payment of the fee and expenses of the arbi-
trator. 
‘‘(5) ENFORCEMENT.—If the Administrator de-
termines that any person seeking to comply with an 
order for testing by relying on a submission made by 
VerDate Mar 15 2010 
02:34 May 19, 2010
Jkt 089200
PO 00000
Frm 00039
Fmt 6652
Sfmt 6201
E:\BILLS\H5320.IH
H5320
PWALKER on DSK8KYBLC1PROD with BILLS
a consortium or an original data submitter has 
failed to make an offer in accordance with para-
graph (3)(B), to participate in an arbitration pro-
ceeding under paragraph (4), or to comply with the 
terms of an agreement or arbitration decision con-
cerning sharing of applicable costs under paragraph 
(3), that person is deemed to have failed to comply 
with an order under subparagraph (A) of section 
408(p)(5) of the Federal Food, Drug, and Cosmetic 
Act for purposes of subparagraphs (B) and (C) of 
such section. 
‘‘(l) DEFINITIONS.—In this section: 
‘‘(1) The term ‘endocrine disruptor’ means an 
exogenous agent or mixture of agents that interferes 
or alters the synthesis, secretion, transport, metabo-
lism, binding action, or elimination of hormones that 
are present in the body and are responsible for ho-
meostasis, growth, neurological signaling, reproduc-
tion and developmental process, or any other effect 
that the Administrator has designated as an ‘endo-
crine effect’ pursuant to section 408(p)(1) of the 
Federal Food, Drug, and Cosmetic Act. 
‘‘(2) The term ‘testing’ means the testing of a 
substance pursuant to the screening program under 
section 408(p) of the Federal Food, Drug, and Cos-
VerDate Mar 15 2010 
02:34 May 19, 2010
Jkt 089200
PO 00000
Frm 00040
Fmt 6652
Sfmt 6201
E:\BILLS\H5320.IH
H5320
PWALKER on DSK8KYBLC1PROD with BILLS
metic Act, including a test of a substance that is in-
tended to identify substances that have the potential 
to interact with the endocrine system or that is in-
tended to determine the endocrine-related effects 
caused by such substance and obtain information 
about effects at various doses. 
‘‘(m) AUTHORIZATION
OF
APPROPRIATIONS.—To 
carry out this section, there is authorized to be appro-
priated $5,000,000 for each of fiscal years 2011 through 
2015.’’. 
Æ 
VerDate Mar 15 2010 
02:34 May 19, 2010
Jkt 089200
PO 00000
Frm 00041
Fmt 6652
Sfmt 6301
E:\BILLS\H5320.IH
H5320
PWALKER on DSK8KYBLC1PROD with BILLS